Deals this week: Genetic Analysis, Boehringer Ingelheim, Vigene Biosciences


Genetic Analysis and Bio-Rad Laboratories have entered an agreement to further develop GA-map technology in routine healthcare.

According to the agreement, Bio-Rad will be responsible for the commercialisation of GA-map technology in some territories, to detect gut Dysbiosis.

Boehringer Ingelheim and China South East University Institute of Life Sciences have entered a research agreement to develop new treatments for hearing loss.

According to the agreement, the two partners will evaluate the key signalling pathways and proteins involved in the regeneration of the inner ear and develop a strategy for drug development.

The agreement enables the partners to regenerate hair cells from inner ear stem cells.

Vigene Biosciences has entered a definitive agreement to acquire cGMP manufacturing facility and other assets from Omnia Biologics.

"Boehringer Ingelheim and China South East University Institute of Life Sciences have entered a research agreement to develop new treatments for hearing loss."

Shulman, Rogers, Gandal, Prody & Ecker PA is acting as legal advisor for the transaction.

The transaction will allow Vigene Biosciences to expand its gene and cell therapy product pipeline.

Laurus Labs Private plans to raise $198m through the initial public offering of its common stock shares.

Citigroup, Jefferies India Private, Kotak Securities and SBI Capital Markets are acting as lead book runners for the offering.

The company plans to use the proceeds for repaying its debts and for general corporate purposes.

Galera Therapeutics has raised $15m in a series B financing round led by Sofinnova Ventures.

The company plans to use proceeds to advance the phase III trials of GC4419 and also to develop its product pipeline for selective dismutase mimetics.